Guardant Health Investor Presentation
JAMA Oncology: Support for a blood first paradigm in NSCLC
University of Pennsylvania study of 323 NSCLC Patients tested with Guardant360
44%
~90%
2x
of eligible patients
didn't get results
from tissue biopsy
Concordance at
diagnosis
reported for
Guardant360Ⓡ
and tissue testing
The number of patients
found with targetable
mutations 82 patients
with Guardant360Ⓡ +
tissue testing versus 47
patients with tissue
testing alone
"These results [Aggarawal et al],
combined with the patient
satisfaction with the relative ease
of providing blood rather than a
solid tissue sample, suggest a
clinical strategy of pursuing
plasma NGS first, then tissue
NGS if plasma NGS cannot
detect relevant mutations."
- Gyawali B and West J, JAMA
Oncology, 2018
11
GUARDANTView entire presentation